Mark Sabag - 05 Mar 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Executive Vice President, International Markets Commercial
Signature
/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag
Issuer symbol
TEVA
Transactions as of
05 Mar 2025
Net transactions value
$0
Form type
4
Filing time
07 Mar 2025, 16:13:23 UTC
Previous filing
06 Mar 2025
Next filing
12 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +23,765 +5.1% 488,911 05 Mar 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -23,765 -100% $0.000000 0 05 Mar 2025 Ordinary Shares 23,765 Direct F1, F2, F3
transaction TEVA Restricted Share Units Award $0 +62,893 $0.000000 62,893 05 Mar 2025 Ordinary Shares 62,893 Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 23,765 vested on March 5, 2025.
F4 Restricted share units were granted on March 5, 2025, with 15,723 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029.

Remarks:

Executive Vice President, International Markets Commercial